This site is for Canadian consumers.
This site is for Canadian consumers.
The COVID-19 virus is still circulating. Is your protection up to date?
Help stay protected against KP.2 variant this season. Talk to your healthcare provider or stop by your local pharmacy and ask about Spikevax.
Book your appointment today.
Why SPIKEVAX?
Some Canadians are still at risk of SARS-CoV-2 infection or severe COVID-19 disease. Vaccinating with SPIKEVAX KP.2 vaccine can help keep you protected against emerging strains.
NACI recommends a COVID-19 vaccine for previously vaccinated and unvaccinated individuals at increased risk of SARS-CoV-2 exposure or severe COVID-19 disease, which includes the following individuals (strong recommendation):
- All adults 65 years of age or older
- Those 6 months of age and older who are:
- Residents of long-term care homes and other congregate living settings;
- Individuals with underlying medical conditions that place them at higher risk of severe COVID-19, including children with complex health needs:
- Pregnant women and individuals who are pregnant;
- Individuals in or from First Nations, Inuit and Métis communities;
- Members of racialized and other equity-denied communities; and
- Health care workers and other care providers in facilities and community settings
For Spring 2025 (April – June 2025)
For those previously vaccinated, most are recommended to receive only one dose per year. However, some populations are recommended to also receive a second annual dose to mitigate the waning protection from COVID-19 vaccines. The following individuals who were previously vaccinated and are at increased risk of severe COVID-19 disease should receive a second dose of COVID-19 vaccine per year:
- Adults 80 years of age and older
- Adult residents of long-term care homes and other congregate living settings for seniors
- Individuals 6 months of age and older who are moderately to severely immunocompromised (due to an underlying condition or treatment)
NACI recommends that all other previously vaccinated and unvaccinated individuals (6 months of age and older) who are not at increased risk for SARS-CoV-2 exposure or severe COVID-19 disease (i.e., not listed above) may receive a COVID-19 vaccine (discretionary recommendation)
For Spring 2025 (April – June 2025)
Previously vaccinated adults 65 to 79 years of age who are at increased risk of severe COVID-19 disease may receive a second dose of COVID-19 vaccine per year (discretionary recommendation).
Vaccination Timing & Considerations
Additionally, the minimum interval between COVID-19 doses is 3 months for previously vaccinated individuals. When deciding on the best time to get vaccinated, individuals can consider factors such as time since their last dose, test-confirmed SARS-CoV-2 infection, local virus circulation, and personal circumstances such as travel, major medical procedures, or large gatherings.
For the full statement please see: Guidance on the use of COVID-19 vaccines for 2025 to summer 2026.
Underlying medical conditions associated with more severe COVID-19 disease
- Cancer
- Cerebrovascular disease
- Chronic kidney disease
- Chronic liver diseases (limited to: cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis)
- Chronic lung diseases (limited to: bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension, pulmonary embolism)
- Cystic fibrosis
- Diabetes mellitus, type 1 and type 2
- Disabilities (e.g. Down syndrome, learning, intellectual, or developmental disabilities; ADHD; cerebral palsy; congenital disabilities; spinal cord injuries)
- Heart conditions (e.g., cardiomyopathies, coronary artery disease, heart failure, etc.)
- HIV infection
- Mental health disorders (limited to: mood disorders, including depression; schizophrenia spectrum disorders)
- Obesity
- Pregnancy and recent pregnancy
- Primary immunodeficiency diseases
- Smoking, current or former
- Solid organ or blood stem cell transplant
- Tuberculosis
- Use of corticosteroids or other immunosuppressive medication
SPIKEVAX COVID-19 Vaccine, mRNA Formula is now available.
SPIKEVAX (COVID-19 Vaccine, mRNA) Formula is an updated vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.¹ Search to find a vaccination site near you, or talk to your healthcare provider.
We're here to help
Get in touch with questions or for any information you may need.
Indication and clinical use
SPIKEVAX® is a vaccine used to prevent COVID-19 caused by the SARS-CoV-2 virus. It can be given to people aged 6 months and older.
The safety and effectiveness of SPIKEVAX mRNA vaccine for individuals 6 months of age and older are inferred from studies of a primary series and booster dose of SPIKEVAX Bivalent in individuals 6 months to 5 years of age, a booster dose of SPIKEVAX Bivalent in individuals >18 years of age, as well as data from studies which evaluated the primary series and booster vaccination with SPIKEVAX.
As with any vaccine, SPIKEVAX may not fully protect all those who receive it. Even after you have had the vaccine, continue to follow the recommendations of local public health officials to prevent the spread of COVID-19. Individuals may not be optimally protected until after receiving the second dose of the vaccine.
The most common or very common side effects of SPIKEVAX are pain at the injection site, tiredness, headache, muscle ache and stiffness, chills, fever, swelling or redness at the injection site, nausea and/or vomiting, enlarged lymph nodes, hypoaesthesia (decreased sense of touch or sensation, numbness) and dizziness. Allergic reactions may also occur.
Vaccination may not be suitable for everyone, so ask your healthcare professional if SPIKEVAX is right for you. Full patient information can be found on spikevax.com/pmi. To report an adverse event, please call 1-866-MODERNA (1-866-663-3762).
Footnotes
*There is limited evidence on clinical risk factors for severe COVID-19 disease in pediatric populations. Children at increased risk for severe outcomes may include children who are medically fragile/have medical complexities, children with more than one comorbidity, children with neurological disorders, children with chronic lung disease, and children with Down syndrome (Trisomy 21), and other immunocompromising conditions.
**Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples Act.
© 2025 ModernaTX, Inc. CA-COV-2300030 04/2025